RPG Active Pharma acquires Raghava API business
Analysis based on 10 articles · First reported Sep 03, 2026 · Last updated Sep 03, 2026
The acquisition strengthens Tiziana Life Sciences' API business, potentially enhancing its market position and growth prospects in the growing API market. The stock rose over 1% on the announcement, reflecting positive investor sentiment, while the deal is expected to contribute to revenue growth once integrated.
Tiziana Life Sciences, through its wholly-owned subsidiary RPG Active Pharma, has entered into a Business Transfer Agreement to acquire the API and intermediates business of Raghava Life Sciences on a going-concern basis via a slump sale for a consideration of up to Rs 135 crore. The acquisition adds a WHO-GMP and EU-GMP approved manufacturing facility near India — Hyderabad with approximately 300 KL installed capacity, a portfolio of 29 API molecules (22 commercialized and 7 under development) across therapeutic areas including diabetes, cardiovascular, and CNS. This is RPG Active Pharma's second acquisition in two months, following its earlier agreement to acquire Actis Generics, as part of a buy-and-build strategy to create an integrated, scaled API organization. The transaction is subject to customary closing conditions and regulatory approvals, and will be funded through a recent equity raise backed by InvAscent. Tiziana Life Sciences' shares rose following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard